Clinical trials
HIV clinical trials
Below are recruiting hiv clinical trials, each written for real people, not researchers. We’re tracking 583 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05674656RecruitingPhase 1/Phase 2
Testing dolutegravir and rilpivirine in HIV-positive children
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
Long Beach, CaliforniaAges 6–12 - NCT07755618Enrolling by invitationPhase 1
Doxycycline levels and adherence study
This study looks at how the antibiotic doxycycline stays in your body and how well people stick to taking it. It may help find better ways to prevent infections.
Chapel Hill, North CarolinaAges 18–65 - NCT07737275Recruiting
Portable x-ray screening for tuberculosis in recent migrants
This trial uses a portable x-ray machine to quickly check for tuberculosis (TB) in people who recently moved to the US. It aims to make TB screening easier and faster for migrants.
New York, New YorkAges 18 years+ - NCT07727642Recruiting
Optimizing HIV Medicines for AIDS-Related Lymphoma
This trial helps doctors find the best way to combine HIV medicines (antiretroviral therapy) with lymphoma treatment for people who have both HIV and AIDS-related lymphoma. The goal is to improve your overall care and outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05515770RecruitingPhase 3
Injectable PrEP shot for HIV prevention in higher-risk adults
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
Rio de JaneiroAges 18–30 - NCT06631365RecruitingPhase 2
PrEP on demand: a pilot study for men who have sex with men
This study tests a '2-1-1' on-demand PrEP strategy for cisgender men who have sex with men. It aims to see if taking PrEP only around the time of sex is safe and effective. If you are interested in starting or currently taking PrEP this way, you may be eligible.
San Francisco, CaliforniaAges 18 years+ - NCT07711223RecruitingPhase 1/Phase 2
New HIV pill compared to standard treatment for untreated adults
This trial compares a new HIV medication (ACC017) to an existing one (dolutegravir) in adults who have HIV but have never taken HIV drugs before. The goal is to see if the new pill works as well and is safe.
BeijingAges 18 years+ - NCT07666386Enrolling by invitation
HIV treatment Biktarvy in early pregnancy
This trial checks if the once-daily HIV pill Biktarvy (B/F/TAF) stays safe and works well for women who are newly pregnant (up to 12 weeks). It is for women already taking Biktarvy with a controlled virus load.
Wuhan, HubeiAges 18 years+ - NCT07636928RecruitingPhase 1
Study of how the body absorbs a new HIV medicine
This early-stage study tests a new HIV medication (VH4524184) to understand how your body absorbs and processes it. You'll take a single dose of the medication with a small amount of radioactive tracer, which helps researchers track where the drug goes in your body.
GroningenAges 18–55 - NCT06691321Recruiting
Caspofungin for Pneumocystis Pneumonia in HIV patients
This trial tests caspofungin, a medicine, for treating Pneumocystis pneumonia (PCP) in people living with HIV. It aims to see if it works better than standard treatments.
Mexico City, TlalpanAges 18–60 - NCT07628140Recruiting
Home-Based TB Prevention Treatment in Kenya
This study tests a community-friendly way to deliver TB prevention medicine (called TPT) to people's homes in Kenya. Researchers want to see if bringing screening and treatment to your house—instead of making you go to a clinic—helps more people start and finish TB prevention, which can reduce TB spread in your community.
KisumuAges Any age - NCT07616739RecruitingPhase 4
Dolutegravir and Lamivudine for Pregnant Women with HIV
This study tests a two-drug HIV treatment combination (dolutegravir and lamivudine) for pregnant women who have never taken HIV medicine before. The goal is to see if this combination safely controls HIV during pregnancy and protects the baby.
Ciudad Autónoma de Buenos Aires, Buenos AiresAges 15 years+ - NCT07596888RecruitingPhase 1
Early safety study of experimental HIV treatment IAP-086-1
This is an early-stage trial testing a new experimental drug (IAP-086-1) in people with HIV who have their virus well-controlled on current medications. Researchers want to understand how safe the drug is and how the body handles it.
Chapel Hill, North CarolinaAges 18–70 - NCT06202898Recruiting
Study helping transgender women access HIV prevention (PrEP)
This study helps transgender women who are not regularly using PrEP (a daily pill to prevent HIV) get access to HIV prevention services. It uses a smartphone to take pictures and connect with support.
Orlando, FloridaAges 18 years+ - NCT07589985Recruiting
Hepatitis B and Liver Health Study in Zambia
This research study follows people with hepatitis B (a liver infection) in Zambia to understand how their bodies respond to treatment and what happens to the virus over time. It includes people with hepatitis B alone, those also living with HIV, and those whose hepatitis B has cleared.
LusakaAges 18 years+ - NCT05985642Recruiting
HIV treatment interruption study for long-term participants
This study looks at people with HIV who have already taken a break from their HIV medications (called an analytic treatment interruption, or ATI) as part of another study. It aims to understand how well the body can control the virus during longer breaks from treatment, up to 96 weeks.
San Francisco, CaliforniaAges 18 years+ - NCT05300035RecruitingPhase 2
HIV treatment add-on antibodies during early infection
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
BobignyAges 18–70 - NCT07525544RecruitingPhase 1
Safety Study of VH4770359 in Healthy Adults
This is an early-stage safety study testing a new investigational drug (VH4770359) in healthy volunteers. Researchers want to understand how the body processes the drug and ensure it is safe and well-tolerated.
Baltimore, MarylandAges 18–55 - NCT07530198RecruitingPhase 1
HIV DNA vaccine test for people on stable treatment
This study tests a new DNA vaccine (ICVAX) designed to help your immune system better control HIV. You'll receive injections over several months if your HIV is well-controlled with current medications.
Shatin, New TerritoriesAges 18–60 - NCT07501624Enrolling by invitation
Pharmacist-led tobacco treatment for HIV patients
This study works with pharmacists at six Ryan White HIV clinics to help people with HIV quit smoking or using tobacco. If you have HIV, are 21 or older, and have already met with a pharmacist about tobacco, you may be able to join.
Charleston, South CarolinaAges 21 years+ - NCT07500415Recruiting
Doxycycline to prevent STIs in Rio de Janeiro
This trial tests whether taking the antibiotic doxycycline can prevent sexually transmitted infections (STIs) like chlamydia, gonorrhea, and syphilis in people at higher risk. If you are a man or transgender woman who has sex with men, are living with HIV or on PrEP, and have had an STI in the past year, you may be able to join.
Rio de Janeiro, Rio de JaneiroAges 18 years+ - NCT07497594Recruiting
Twice-yearly shots to prevent HIV
This trial tests a new HIV prevention medicine called lenacapavir, given as a shot every six months. It's for young people at risk of HIV who haven't used PrEP before or have had gaps in their PrEP use.
Manaus, AmazonasAges 16–30 - NCT07486661Recruiting
Preventing frailty in people with HIV aged 65-75
This study aims to help people with HIV between the ages of 65 and 75 stay healthy and avoid becoming frail as they age. It tests a program to prevent frailty and see if it works.
BrusselsAges 65–74 - NCT07467018Recruiting
Mobile van study of a long-acting HIV prevention shot
This study tests if giving a long-acting HIV prevention shot (lenacapavir) from a mobile medical van can reach people at risk for HIV in Los Angeles County. You may be able to join if you are HIV negative, at risk for HIV, and are willing to try a shot instead of a daily pill.
Santa Monica, CaliforniaAges 18 years+
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hiv?
- Yes. Clin2 currently lists 583 recruiting hiv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hiv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hiv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.